Elsubrutinib

DB18850InvestigationalSmall molecule

Elsubrutinib is under investigation in clinical trial NCT04451772 (A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants...

Mechanism: Pharmacologically active on Tyrosine-protein kinase BTK
Curator reviewed
Formula / weight: C₁₇H₁₉N₃O₂ · 297.358 g/mol (avg)
Also known as: (s)-4-(1-acryloylpiperidin-3-yl)-1h-indole-7-carboxamide · 1h-indole-7-carboxamide, 4-((3s)-1-(1-oxo-2-propen-1-yl)-3-piperidinyl)- · 4-((3s)-1-(prop-2-enoyl)-piperidin-3-yl)-1h-indole-7-carboxamide
Code names: ABBV-105

Resolves to

Compound

UNII1487U1Q3IQCAS1643570-24-4ChEMBLCHEMBL4594348

Structure

InChIKeyUNHZLHSLZZWMNP-LLVKDONJSA-NSMILESNC(=O)C1=C2NC=CC2=C(C=C1)[C@@H]1CCCN(C1)C(=O)C=C

Targets

Q06187BTK

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Elsubrutinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account